Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex | Zendy

Mari WatayaKaneda | Zendy; Yuuki Ohno | Zendy; Yasuyuki Fujita | Zendy; Hiroo Yokozeki | Zendy; Hironori Niizeki | Zendy; Masaaki Ogai | Zendy; Kazuyoshi Fukai | Zendy; Hiroshi Nagai | Zendy; Yuichi Yoshida | Zendy; Izumi Hamada | Zendy; Taihei Hio | Zendy; Kenji Shimizu | Zendy; Hiroyuki Murota | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Sirolimus Gel Treatment vs Placebo for Facial Angiofibromas in Patients With Tuberous Sclerosis Complex

Author(s) -

Mari WatayaKaneda,

Yuuki Ohno,

Yasuyuki Fujita,

Hiroo Yokozeki,

Hironori Niizeki,

Masaaki Ogai,

Kazuyoshi Fukai,

Hiroshi Nagai,

Yuichi Yoshida,

Izumi Hamada,

Taihei Hio,

Kenji Shimizu,

Hiroyuki Murota

Publication year - 2018

Publication title -

jama dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.128

H-Index - 166

eISSN - 2168-6084

pISSN - 2168-6068

DOI - 10.1001/jamadermatol.2018.1408

Subject(s) - medicine , tuberous sclerosis , sirolimus , dermatology , placebo , angiofibroma , surgery , pathology , alternative medicine

Most patients with tuberous sclerosis complex (TSC), an autosomal-dominant disorder that is caused by the constitutive activation of mammalian target of rapamycin, experience disfigurement caused by skin lesions involving facial angiofibromas. Many have been left untreated because of a lack of therapeutic options that are less invasive than surgery or laser treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research